Previous Close | 32.63 |
Open | 31.50 |
Bid | 31.33 x 100 |
Ask | 31.60 x 100 |
Day's Range | 30.23 - 32.39 |
52 Week Range | 6.40 - 35.98 |
Volume | |
Avg. Volume | 1,318,114 |
Market Cap | 2.75B |
Beta (5Y Monthly) | 1.00 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.
Top-notch biotech stock Dyne broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy drugs.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...